Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Tumor marker downclassification

This article was originally published in The Gray Sheet

Executive Summary

Tumor marker downclassification: FDA announces availability of its "Guidance Document for the Submission of Tumor Associated Antigen Pre-Market Notifications, 510(k) to FDA" in the Dec. 17 Federal Register. The agency also codifies in a separate announcement the downclassification of tumor markers used as "an aid in monitoring patients for disease progression or response to therapy or for the detection of recurrent or residual disease" from Class III to Class II ("The Gray Sheet" Sept. 23, 1996, I&W-1). The regulation appears in 21 CFR Section 866.6010...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT009377

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel